A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported…

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, March 2018

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 11,414 followers.

《短報》【HER2陰性乳がん：一次・二次治療】「ハラヴェン」治療の奏効率37.1％、病勢コントロール率54.3％、無増悪生存期間6.2ヵ月、生存期間21.4ヵ月。日本のPhase 2試験の結果。〔Cancer Chemother Pharmacol〕 https://t.co/CNIT7drQPM